key: cord-278938-bmahwxbn
authors: Masi, Davide; Risi, Renata; Gnessi, Lucio; Watanabe, Mikiko; Mariani, Stefania; Lubrano, Carla
title: Letter To the Editor: [Our Response to COVID-19 as Endocrinologists and Diabetologists]
date: 2020-04-28
journal: J Clin Endocrinol Metab
DOI: 10.1210/clinem/dgaa229
sha: 
doc_id: 278938
cord_uid: bmahwxbn

nan

M a n u s c r i p t 2 We read with interest the article by Kaiser et al. highlighting some relevant aspects about the management of patients with endocrine conditions who are simultaneously infected with the 2019 novel coronavirus (SARS-CoV-2). 1 As far as we are concerned, understanding the evidence of the role played by corticosteroids in SARS-CoV-2 infection is of immediate clinical importance. The existing literature does not currently provide conclusive evidence regarding their administration for the treatment of COVID-19. 2 There have been a number of reports stating generally positive outcomes upon corticosteroids use especially in the early acute phase of infection, as they are capable of reducing immune-mediated damage 3 . In this regard, Fu Y et al. suggest to adopt steroids in combination with the use of intravenous immunoglobulin to block Fc receptors (FcR) activation in order to prevent severe lung injury. However, such treatment remains to be clinically tested for effectiveness. 4 On the other hand, patients taking supra-physiologic doses of glucocorticoids may have increased susceptibility to COVID-19 because of the immunosuppressive effects of steroids, which can be ultimately responsible for severe lymphocytopenia, thus promoting a viral rebound. Moreover, steroids have also been associated with higher risk of acute respiratory distress syndrome (ARDS) 5 and may therefore determine exaggerated proinflammatory responses and even worsen the clinical condition of the patients.

However, in the event of COVID-19, patients on long-term steroids, or suffering from adrenal insufficiency and uncontrolled Cushing syndrome may be unable to develop a normal stress response, thus requiring a rescue dose of glucocorticoids. 1 In our opinion, this evidence by Kaiser and colleagues should be extended to those patients with chronic pain on therapy with opioids. Longterm use of opioids has been associated with suppression of the hypothalamicpituitary-adrenal (HPA) axis through the inhibition of corticotrophin-releasing hormone (CRH) and antidiuretic hormone (ADH) secretion, resulting in decreased adrenocorticotropic hormone (ACTH) release 6 and central M a n u s c r i p t

Our Response to COVID-19 as Endocrinologists and Diabetologists

COVID-19 and treatment with NSAIDs and corticosteroids : should we be limiting their use in the clinical setting ? Ecancer

Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence

Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

Opioid-induced endocrinopathies

Endocrine consequences of long-term intrathecal administration of opioids

Chronic Spinal and Oral Morphine-Induced Neuroendocrine and Metabolic Changes in Noncancer Pain Patients

A c c e p t e d M a n u s c r i p t 4